Proteome Sciences PLC Result of GM and Completion of Placing (4312Q)
29 November 2016 - 10:43AM
UK Regulatory
TIDMPRM
RNS Number : 4312Q
Proteome Sciences PLC
29 November 2016
Proteome Sciences plc
("Company" or the "Group")
Result of General Meeting and Completion of Placing
29 November 2016: Proteome Sciences plc (AIM:PRM) is pleased to
announce that at its General Meeting held earlier today, all
resolutions were duly passed.
Accordingly, and as set out in the announcement dated 31 October
2016 (the "Announcement"), the Company now has the requisite
authorities to complete the second tranche of the placing and
subscription of 66,258,100 new ordinary shares of 1 pence each in
the capital of the Company ("Ordinary Shares") with new and
existing shareholders at a price of 5 pence per Ordinary Share to
raise, in aggregate, GBP3.3 million before expenses (the
"Fundraise").
The net proceeds of the Fundraise will be used to accelerate the
Company's evolution into a premium contract, service-based
biomarker business, underpinned with a bioinformatics capability
whilst ensuring that the Company has the capacity to meet Thermo
Fisher Scientific's further demand for its TMT reagents.
As an amendment to the Announcement, Vulpes Life Science Fund (a
participant in the Fundraise of which Martin Diggle, Non-Executive
Director of the Company, is a director and beneficiary) is
expecting to delay its funding by one week due to the completion of
a corporate restructuring of its Investment Manager in Singapore.
Accordingly, the 20,664,754 new Ordinary Shares issued pursuant to
the second tranche of the Fundraise are now expected to be admitted
to trading on AIM at 8.00 a.m. on 16 December 2016 ("Admission").
Following Admission, the Company will have 294,324,832 Ordinary
Shares in issue, all with voting rights. The Company does not hold
any shares in treasury.
The above figure of 294,324,832 Ordinary Shares may be used by
shareholders as the denominator for the calculation by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the Company under the FCA's
Disclosure and Transparency Rules.
For further information:
Proteome Sciences plc
Jeremy Haigh, Chief Executive Officer
Ian Pike, Chief Scientific Officer Tel: +44 (0)1932 865065
Geoff Ellis, Chief Financial Officer
finnCap Ltd (Nominated adviser & Broker)
Geoff Nash/James Thompson Tel : +44 (0)20 7220 0500
Tony Quirke (Broking)
IFC Advisory (Public Relations) Tel : +44 (0) 203 053 8671
Tim Metcalfe/Graham Herring/Miles
Nolan
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences is a leader in applied proteomics offering
high sensitivity, proprietary technologies and workflows for
mapping cell signalling pathways (SysQuant(R) , TMTcalibrator(TM) )
and for the discovery, validation and assay development of protein
biomarkers. The company has its headquarters in Cobham, UK, with
laboratory facilities in London, UK and in Frankfurt, Germany from
where the PS Biomarker Services(TM) division provides outsourced
proteomics services and proprietary biomarker assays to
biopharmaceutical and diagnostics companies and to academia.
Proteome Sciences has patented a number of novel protein
biomarkers for diagnostic and treatment applications in important
areas of human therapeutics such as cancer, stroke and Alzheimer's
disease, and these are available for license.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBKLFLQFFZFBB
(END) Dow Jones Newswires
November 29, 2016 05:43 ET (10:43 GMT)